BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26967531)

  • 1. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.
    Claussen C; Rausch AV; Lezius S; Amirkhosravi A; Davila M; Francis JL; Hisada YM; Mackman N; Bokemeyer C; Schmalfeldt B; Mahner S; Langer F
    Thromb Res; 2016 May; 141():39-48. PubMed ID: 26967531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses.
    Amirkhosravi A; Bigsby G; Desai H; Rivera-Amaya M; Coll E; Robles-Carrillo L; Faust P; Waters A; Meyer T; Reyes E; Langer F; Francis JL
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):510-7. PubMed ID: 23406663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
    Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
    J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
    Riva N; Vella K; Hickey K; Bertù L; Zammit D; Spiteri S; Kitchen S; Makris M; Ageno W; Gatt A
    J Clin Pathol; 2018 Nov; 71(11):1015-1022. PubMed ID: 30093507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
    Khorana AA; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Lee AY
    J Clin Oncol; 2017 Apr; 35(10):1078-1085. PubMed ID: 28029329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Cohen JG; Prendergast E; Geddings JE; Walts AE; Agadjanian H; Hisada Y; Karlan BY; Mackman N; Walsh CS
    Gynecol Oncol; 2017 Jul; 146(1):146-152. PubMed ID: 28501328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of silent venous thromboembolism before treatment in ovarian cancer.
    Satoh T; Oki A; Uno K; Sakurai M; Ochi H; Okada S; Minami R; Matsumoto K; Tanaka YO; Tsunoda H; Homma S; Yoshikawa H
    Br J Cancer; 2007 Oct; 97(8):1053-7. PubMed ID: 17895896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of risk factors for venous thromboembolism in Chinese women with epithelial ovarian cancer.
    Wu X; Xue X; Tang J; Cheng X; Tian W; Jiang R; Zang R
    Int J Gynecol Cancer; 2013 Jan; 23(1):65-72. PubMed ID: 23196757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult cancer in patients with unprovoked venous thromboembolism: A nested case-control study.
    Sánchez-López V; Marín-Romero S; Ferrer-Galván M; Elías-Hernández T; Lobo Beristain JL; Ballaz Quincoces A; Jara-Palomares L; Rodríguez Martorell FJ; Castro MJ; Marín Hinojosa C; López-Campos JL; Otero-Candelera R
    Am J Clin Pathol; 2024 May; 161(5):501-511. PubMed ID: 38340336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microparticles in patients with benign and malignant ovarian tumors.
    Rank A; Liebhardt S; Zwirner J; Burges A; Nieuwland R; Toth B
    Anticancer Res; 2012 May; 32(5):2009-14. PubMed ID: 22593480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
    Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
    Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
    Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
    Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
    Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
    Haubold K; Rink M; Spath B; Friedrich M; Chun FK; Marx G; Amirkhosravi A; Francis JL; Bokemeyer C; Eifrig B; Langer F
    Thromb Haemost; 2009 Jun; 101(6):1147-55. PubMed ID: 19492160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High concentration of the plasma microparticles for venous thromboembolism associated with lung cancer.
    Wang M; Huang X; Zhu M; Zhang S; Zhang Y
    Clin Respir J; 2020 May; 14(5):481-487. PubMed ID: 32031323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
    Reitter EM; Kaider A; Ay C; Quehenberger P; Marosi C; Zielinski C; Pabinger I
    J Thromb Haemost; 2016 Feb; 14(2):294-305. PubMed ID: 26662117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
    Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
    Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty.
    Johnson GJ; Leis LA; Bach RR
    Thromb Haemost; 2009 Oct; 102(4):728-34. PubMed ID: 19806259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.
    Ades S; Douce D; Holmes CE; Cory S; Prior S; Butenas S; Callas P; Cushman M
    J Thromb Haemost; 2018 Jun; 16(6):1099-1106. PubMed ID: 29575637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.